Article Summary –
U.S. Senator Sherrod Brown, has been advocating for lower insulin prices for all Ohioans. The Inflation Reduction Act, which Brown helped write and pass, has allowed for a monthly cap on the cost of insulin at $35, significantly lowering costs for Ohioans on Medicare. Brown continues to push for this price cap to be extended to all Americans, and is also supporting other legislation and amendments to further reduce healthcare and prescription drug costs.
U.S. Senator Advocates for Lower Insulin Prices Under the Inflation Reduction Act
U.S. Senator Sherrod Brown (D-OH) recently joined key figures at the Neighborhood Health Association to underscore his ongoing effort to reduce insulin prices. Brown highlighted how the Inflation Reduction Act, which he significantly contributed to, has made an impact on lowering insulin costs, especially for Ohioans on Medicare.
“After years of combating opposition from Big Pharma, we succeeded in cutting insulin costs for older Ohioans. I’m committed to extending this cost limit to all Ohioans so nobody pays over $35 a month for this vital medication,” said Brown.
Brown has consistently fought for affordable insulin and endorses legislation to cap the cost at $35 for all. He also supported an amendment to the Inflation Reduction Act that would expand the $35 monthly insulin cost cap to all Americans.
Doni Miller, CEO of Neighborhood Health Association, commented, “Cap on insulin costs means acknowledging that the cost of medication is a matter of life and death.” Gregory Kramp, PharmD, RPh, noted, “The Insulin Reduction Act has helped many seniors avoid choosing between food and medicine.”
Terry Hinkle, an Ohioan Medicare Beneficiary, expressed gratitude for the price cut, “I couldn’t afford insulin without this price cut. I thank Sherrod Brown for initiating it.”
Brown’s Fight Against Big Pharma
In the Inflation Reduction Act, Brown ensured that Medicare can negotiate directly with pharmaceutical companies to reduce prescription drug costs for Ohioans. The Act also requires that companies raising their prices faster than inflation pay a rebate to lower costs for patients and taxpayers. By 2025, the law will cap Medicare’s out-of-pocket drug costs at $2,000.
Brown has consistently worked on lowering drug costs and confronted abusive pharmacy benefit manager (PBM) practices. In 2023, Brown championed PBM reform and introducedbipartisan legislation to reduce out-of-pocket costs for medicines for chronic conditions. As part of these measures, he fought for thePharmacy DIR Reform to Reduce Senior Drug Costs Act, which aims to lower costs for older Ohioans.
—
Read More Kitchen Table News
